Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Mission Possible: Advances in MYC Therapeutic Targeting in Cancer.

Allen-Petersen BL, Sears RC.

BioDrugs. 2019 Aug 7. doi: 10.1007/s40259-019-00370-5. [Epub ahead of print] Review.

PMID:
31392631
2.

The role of lineage plasticity in prostate cancer therapy resistance.

Beltran H, Hruszkewycz A, Scher HI, Hildesheim J, Isaacs J, Yu EY, Kelly K, Lin D, Dicker AP, Arnold JT, Hecht TT, Wicha MS, Sears RC, Rowley DR, White RM, Gulley JL, Lee JK, Diaz-Meco MT, Small EJ, Shen MM, Knudsen KE, Goodrich DW, Lotan TL, Zoubeidi A, Sawyers CL, Rudin CM, Loda M, Thompson TC, Rubin MA, Tawab-Amiri A, Dahut W, Nelson PS.

Clin Cancer Res. 2019 Jul 30. pii: clincanres.1423.2019. doi: 10.1158/1078-0432.CCR-19-1423. [Epub ahead of print]

PMID:
31363002
3.

Innate αβ T cells Mediate Antitumor Immunity by Orchestrating Immunogenic Macrophage Programming.

Hundeyin M, Kurz E, Mishra A, Kochen Rossi JA, Liudahl SM, Leis KR, Mehrotra H, Kim M, Torres LE, Ogunsakin A, Link J, Sears RC, Sivagnanam S, Goecks J, Islam KS, Dolgalev I, Savadkar S, Wang W, Aykut B, Leinwand J, Diskin B, Adam S, Israr M, Gelas M, Lish J, Chin K, Farooq MS, Wadowski B, Wu J, Shah S, Adeegbe DO, Pushalkar S, Vasudevaraja V, Saxena D, Wong KK, Coussens LM, Miller G.

Cancer Discov. 2019 Jul 2. pii: CD-19-0161. doi: 10.1158/2159-8290.CD-19-0161. [Epub ahead of print]

PMID:
31266770
4.

The use of protein phosphatase 2A activators in combination therapies for pancreas cancer.

Allen-Petersen BL, Sears RC.

Oncotarget. 2019 Mar 12;10(21):2008-2009. doi: 10.18632/oncotarget.26772. eCollection 2019 Mar 12. No abstract available.

5.

Myc and Loss of p53 Cooperate to Drive Formation of Choroid Plexus Carcinoma.

Wang J, Merino DM, Light N, Murphy BL, Wang YD, Guo X, Hodges AP, Chau LQ, Liu KW, Dhall G, Asgharzadeh S, Kiehna EN, Shirey RJ, Janda KD, Taylor MD, Malkin D, Ellison DW, VandenBerg SR, Eberhart CG, Sears RC, Roussel MF, Gilbertson RJ, Wechsler-Reya RJ.

Cancer Res. 2019 May 1;79(9):2208-2219. doi: 10.1158/0008-5472.CAN-18-2565. Epub 2019 Mar 18.

PMID:
30885981
6.

Modeling differentiation-state transitions linked to therapeutic escape in triple-negative breast cancer.

Chapman MP, Risom T, Aswani AJ, Langer EM, Sears RC, Tomlin CJ.

PLoS Comput Biol. 2019 Mar 11;15(3):e1006840. doi: 10.1371/journal.pcbi.1006840. eCollection 2019 Mar.

7.

A Stromal Lysolipid-Autotaxin Signaling Axis Promotes Pancreatic Tumor Progression.

Auciello FR, Bulusu V, Oon C, Tait-Mulder J, Berry M, Bhattacharyya S, Tumanov S, Allen-Petersen BL, Link J, Kendsersky ND, Vringer E, Schug M, Novo D, Hwang RF, Evans RM, Nixon C, Dorrell C, Morton JP, Norman JC, Sears RC, Kamphorst JJ, Sherman MH.

Cancer Discov. 2019 May;9(5):617-627. doi: 10.1158/2159-8290.CD-18-1212. Epub 2019 Mar 5.

PMID:
30837243
8.

Modeling Tumor Phenotypes In Vitro with Three-Dimensional Bioprinting.

Langer EM, Allen-Petersen BL, King SM, Kendsersky ND, Turnidge MA, Kuziel GM, Riggers R, Samatham R, Amery TS, Jacques SL, Sheppard BC, Korkola JE, Muschler JL, Thibault G, Chang YH, Gray JW, Presnell SC, Nguyen DG, Sears RC.

Cell Rep. 2019 Jan 15;26(3):608-623.e6. doi: 10.1016/j.celrep.2018.12.090.

9.

Activation of PP2A and Inhibition of mTOR Synergistically Reduce MYC Signaling and Decrease Tumor Growth in Pancreatic Ductal Adenocarcinoma.

Allen-Petersen BL, Risom T, Feng Z, Wang Z, Jenny ZP, Thoma MC, Pelz KR, Morton JP, Sansom OJ, Lopez CD, Sheppard B, Christensen DJ, Ohlmeyer M, Narla G, Sears RC.

Cancer Res. 2019 Jan 1;79(1):209-219. doi: 10.1158/0008-5472.CAN-18-0717. Epub 2018 Nov 2.

PMID:
30389701
10.

Post-translational modification localizes MYC to the nuclear pore basket to regulate a subset of target genes involved in cellular responses to environmental signals.

Su Y, Pelz C, Huang T, Torkenczy K, Wang X, Cherry A, Daniel CJ, Liang J, Nan X, Dai MS, Adey A, Impey S, Sears RC.

Genes Dev. 2018 Nov 1;32(21-22):1398-1419. doi: 10.1101/gad.314377.118. Epub 2018 Oct 26.

11.

SUMO protease SENP1 deSUMOylates and stabilizes c-Myc.

Sun XX, Chen Y, Su Y, Wang X, Chauhan KM, Liang J, Daniel CJ, Sears RC, Dai MS.

Proc Natl Acad Sci U S A. 2018 Oct 23;115(43):10983-10988. doi: 10.1073/pnas.1802932115. Epub 2018 Oct 10.

12.

Differentiation-state plasticity is a targetable resistance mechanism in basal-like breast cancer.

Risom T, Langer EM, Chapman MP, Rantala J, Fields AJ, Boniface C, Alvarez MJ, Kendsersky ND, Pelz CR, Johnson-Camacho K, Dobrolecki LE, Chin K, Aswani AJ, Wang NJ, Califano A, Lewis MT, Tomlin CJ, Spellman PT, Adey A, Gray JW, Sears RC.

Nat Commun. 2018 Sep 19;9(1):3815. doi: 10.1038/s41467-018-05729-w.

13.

Proteomics, Post-translational Modifications, and Integrative Analyses Reveal Molecular Heterogeneity within Medulloblastoma Subgroups.

Archer TC, Ehrenberger T, Mundt F, Gold MP, Krug K, Mah CK, Mahoney EL, Daniel CJ, LeNail A, Ramamoorthy D, Mertins P, Mani DR, Zhang H, Gillette MA, Clauser K, Noble M, Tang LC, Pierre-François J, Silterra J, Jensen J, Tamayo P, Korshunov A, Pfister SM, Kool M, Northcott PA, Sears RC, Lipton JO, Carr SA, Mesirov JP, Pomeroy SL, Fraenkel E.

Cancer Cell. 2018 Sep 10;34(3):396-410.e8. doi: 10.1016/j.ccell.2018.08.004.

PMID:
30205044
14.

Serum Biomarker Signature-Based Liquid Biopsy for Diagnosis of Early-Stage Pancreatic Cancer.

Mellby LD, Nyberg AP, Johansen JS, Wingren C, Nordestgaard BG, Bojesen SE, Mitchell BL, Sheppard BC, Sears RC, Borrebaeck CAK.

J Clin Oncol. 2018 Oct 1;36(28):2887-2894. doi: 10.1200/JCO.2017.77.6658. Epub 2018 Aug 14.

PMID:
30106639
15.

The ubiquitin-specific protease USP36 is a conserved histone H2B deubiquitinase.

DeVine T, Sears RC, Dai MS.

Biochem Biophys Res Commun. 2018 Jan 15;495(3):2363-2368. doi: 10.1016/j.bbrc.2017.12.107. Epub 2017 Dec 20.

16.

The tumor suppressor phosphatase PP2A-B56α regulates stemness and promotes the initiation of malignancies in a novel murine model.

Janghorban M, Langer EM, Wang X, Zachman D, Daniel CJ, Hooper J, Fleming WH, Agarwal A, Sears RC.

PLoS One. 2017 Nov 30;12(11):e0188910. doi: 10.1371/journal.pone.0188910. eCollection 2017.

17.

MYC regulates ductal-neuroendocrine lineage plasticity in pancreatic ductal adenocarcinoma associated with poor outcome and chemoresistance.

Farrell AS, Joly MM, Allen-Petersen BL, Worth PJ, Lanciault C, Sauer D, Link J, Pelz C, Heiser LM, Morton JP, Muthalagu N, Hoffman MT, Manning SL, Pratt ED, Kendsersky ND, Egbukichi N, Amery TS, Thoma MC, Jenny ZP, Rhim AD, Murphy DJ, Sansom OJ, Crawford HC, Sheppard BC, Sears RC.

Nat Commun. 2017 Nov 23;8(1):1728. doi: 10.1038/s41467-017-01967-6.

18.

ZEB1-repressed microRNAs inhibit autocrine signaling that promotes vascular mimicry of breast cancer cells.

Langer EM, Kendsersky ND, Daniel CJ, Kuziel GM, Pelz C, Murphy KM, Capecchi MR, Sears RC.

Oncogene. 2018 Feb 22;37(8):1005-1019. doi: 10.1038/onc.2017.356. Epub 2017 Oct 30.

19.

Activation of tumor suppressor protein PP2A inhibits KRAS-driven tumor growth.

Sangodkar J, Perl A, Tohme R, Kiselar J, Kastrinsky DB, Zaware N, Izadmehr S, Mazhar S, Wiredja DD, O'Connor CM, Hoon D, Dhawan NS, Schlatzer D, Yao S, Leonard D, Borczuk AC, Gokulrangan G, Wang L, Svenson E, Farrington CC, Yuan E, Avelar RA, Stachnik A, Smith B, Gidwani V, Giannini HM, McQuaid D, McClinch K, Wang Z, Levine AC, Sears RC, Chen EY, Duan Q, Datt M, Haider S, Ma'ayan A, DiFeo A, Sharma N, Galsky MD, Brautigan DL, Ioannou YA, Xu W, Chance MR, Ohlmeyer M, Narla G.

J Clin Invest. 2017 Jun 1;127(6):2081-2090. doi: 10.1172/JCI89548. Epub 2017 May 15.

20.

Aspirin therapy reduces the ability of platelets to promote colon and pancreatic cancer cell proliferation: Implications for the oncoprotein c-MYC.

Mitrugno A, Sylman JL, Ngo AT, Pang J, Sears RC, Williams CD, McCarty OJ.

Am J Physiol Cell Physiol. 2017 Feb 1;312(2):C176-C189. doi: 10.1152/ajpcell.00196.2016. Epub 2016 Nov 30.

21.

MYC is not detected in highly proliferating normal spermatogonia but is coupled with CIP2A in testicular cancers.

Ventelä S, Mäkelä JA, Sears RC, Toppari J, Westermarck J.

Matters (Zur). 2016 Mar;2016. doi: 10.19185/matters.201602000040. Epub 2016 Mar 3.

22.

Deubiquitinating c-Myc: USP36 steps up in the nucleolus.

Sun XX, Sears RC, Dai MS.

Cell Cycle. 2015;14(24):3786-93. doi: 10.1080/15384101.2015.1093713.

23.

Pre-Anchoring of Pin1 to Unphosphorylated c-Myc in a Fuzzy Complex Regulates c-Myc Activity.

Helander S, Montecchio M, Pilstål R, Su Y, Kuruvilla J, Elvén M, Ziauddin JME, Anandapadamanaban M, Cristobal S, Lundström P, Sears RC, Wallner B, Sunnerhagen M.

Structure. 2015 Dec 1;23(12):2267-2279. doi: 10.1016/j.str.2015.10.010. Epub 2015 Nov 19.

24.

Serine 62-Phosphorylated MYC Associates with Nuclear Lamins and Its Regulation by CIP2A Is Essential for Regenerative Proliferation.

Myant K, Qiao X, Halonen T, Come C, Laine A, Janghorban M, Partanen JI, Cassidy J, Ogg EL, Cammareri P, Laiterä T, Okkeri J, Klefström J, Sears RC, Sansom OJ, Westermarck J.

Cell Rep. 2015 Aug 11;12(6):1019-31. doi: 10.1016/j.celrep.2015.07.003. Epub 2015 Jul 30.

25.

Identification of a Potent Inhibitor of CREB-Mediated Gene Transcription with Efficacious in Vivo Anticancer Activity.

Xie F, Li BX, Kassenbrock A, Xue C, Wang X, Qian DZ, Sears RC, Xiao X.

J Med Chem. 2015 Jun 25;58(12):5075-87. doi: 10.1021/acs.jmedchem.5b00468. Epub 2015 Jun 5.

26.

The nucleolar ubiquitin-specific protease USP36 deubiquitinates and stabilizes c-Myc.

Sun XX, He X, Yin L, Komada M, Sears RC, Dai MS.

Proc Natl Acad Sci U S A. 2015 Mar 24;112(12):3734-9. doi: 10.1073/pnas.1411713112. Epub 2015 Mar 9.

27.

Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer.

Janghorban M, Farrell AS, Allen-Petersen BL, Pelz C, Daniel CJ, Oddo J, Langer EM, Christensen DJ, Sears RC.

Proc Natl Acad Sci U S A. 2014 Jun 24;111(25):9157-62. doi: 10.1073/pnas.1317630111. Epub 2014 Jun 9.

28.

Targeting inhibitors of the tumor suppressor PP2A for the treatment of pancreatic cancer.

Farrell AS, Allen-Petersen B, Daniel CJ, Wang X, Wang Z, Rodriguez S, Impey S, Oddo J, Vitek MP, Lopez C, Christensen DJ, Sheppard B, Sears RC.

Mol Cancer Res. 2014 Jun;12(6):924-39. doi: 10.1158/1541-7786.MCR-13-0542. Epub 2014 Mar 25.

29.

MYC degradation.

Farrell AS, Sears RC.

Cold Spring Harb Perspect Med. 2014 Mar 1;4(3). pii: a014365. doi: 10.1101/cshperspect.a014365. Review.

30.

Diminished WNT -> β-catenin -> c-MYC signaling is a barrier for malignant progression of BRAFV600E-induced lung tumors.

Juan J, Muraguchi T, Iezza G, Sears RC, McMahon M.

Genes Dev. 2014 Mar 15;28(6):561-75. doi: 10.1101/gad.233627.113. Epub 2014 Mar 3.

31.

Detection of c-Myc protein-protein interactions and phosphorylation status by immunoprecipitation.

Daniel CJ, Zhang X, Sears RC.

Methods Mol Biol. 2013;1012:65-76. doi: 10.1007/978-1-62703-429-6_5.

PMID:
24006058
32.

Pin1 regulates the dynamics of c-Myc DNA binding to facilitate target gene regulation and oncogenesis.

Farrell AS, Pelz C, Wang X, Daniel CJ, Wang Z, Su Y, Janghorban M, Zhang X, Morgan C, Impey S, Sears RC.

Mol Cell Biol. 2013 Aug;33(15):2930-49. doi: 10.1128/MCB.01455-12. Epub 2013 May 28.

33.

N terminus of ASPP2 binds to Ras and enhances Ras/Raf/MEK/ERK activation to promote oncogene-induced senescence.

Wang Z, Liu Y, Takahashi M, Van Hook K, Kampa-Schittenhelm KM, Sheppard BC, Sears RC, Stork PJ, Lopez CD.

Proc Natl Acad Sci U S A. 2013 Jan 2;110(1):312-7. doi: 10.1073/pnas.1201514110. Epub 2012 Dec 17.

34.

A critical role for Mnt in Myc-driven T-cell proliferation and oncogenesis.

Link JM, Ota S, Zhou ZQ, Daniel CJ, Sears RC, Hurlin PJ.

Proc Natl Acad Sci U S A. 2012 Nov 27;109(48):19685-90. doi: 10.1073/pnas.1206406109. Epub 2012 Nov 12.

35.

Studying c-Myc serine 62 phosphorylation in leukemia cells: concern over antibody cross-reactivity.

Tibbitts DC, Escamilla-Powers JR, Zhang X, Sears RC.

Blood. 2012 May 31;119(22):5334-5. doi: 10.1182/blood-2012-03-414532. No abstract available.

36.

PP2A-B56α controls oncogene-induced senescence in normal and tumor human melanocytic cells.

Mannava S, Omilian AR, Wawrzyniak JA, Fink EE, Zhuang D, Miecznikowski JC, Marshall JR, Soengas MS, Sears RC, Morrison CD, Nikiforov MA.

Oncogene. 2012 Mar 22;31(12):1484-92. doi: 10.1038/onc.2011.339. Epub 2011 Aug 8.

37.

Ribosomal protein L11 recruits miR-24/miRISC to repress c-Myc expression in response to ribosomal stress.

Challagundla KB, Sun XX, Zhang X, DeVine T, Zhang Q, Sears RC, Dai MS.

Mol Cell Biol. 2011 Oct;31(19):4007-21. doi: 10.1128/MCB.05810-11. Epub 2011 Aug 1.

38.

Overcoming hypoxia-induced apoptotic resistance through combinatorial inhibition of GSK-3β and CDK1.

Mayes PA, Dolloff NG, Daniel CJ, Liu JJ, Hart LS, Kuribayashi K, Allen JE, Jee DI, Dorsey JF, Liu YY, Dicker DT, Brown JM, Furth EE, Klein PS, Sears RC, El-Deiry WS.

Cancer Res. 2011 Aug 1;71(15):5265-75. doi: 10.1158/0008-5472.CAN-11-1383. Epub 2011 Jun 6.

39.

Phosphorylation regulates c-Myc's oncogenic activity in the mammary gland.

Wang X, Cunningham M, Zhang X, Tokarz S, Laraway B, Troxell M, Sears RC.

Cancer Res. 2011 Feb 1;71(3):925-36. doi: 10.1158/0008-5472.CAN-10-1032. Epub 2011 Jan 25.

40.

Focal adhesion kinase is required for intestinal regeneration and tumorigenesis downstream of Wnt/c-Myc signaling.

Ashton GH, Morton JP, Myant K, Phesse TJ, Ridgway RA, Marsh V, Wilkins JA, Athineos D, Muncan V, Kemp R, Neufeld K, Clevers H, Brunton V, Winton DJ, Wang X, Sears RC, Clarke AR, Frame MC, Sansom OJ.

Dev Cell. 2010 Aug 17;19(2):259-69. doi: 10.1016/j.devcel.2010.07.015.

41.

The Axin1 scaffold protein promotes formation of a degradation complex for c-Myc.

Arnold HK, Zhang X, Daniel CJ, Tibbitts D, Escamilla-Powers J, Farrell A, Tokarz S, Morgan C, Sears RC.

EMBO J. 2009 Mar 4;28(5):500-12. doi: 10.1038/emboj.2008.279. Epub 2009 Jan 8.

42.

Global rank-invariant set normalization (GRSN) to reduce systematic distortions in microarray data.

Pelz CR, Kulesz-Martin M, Bagby G, Sears RC.

BMC Bioinformatics. 2008 Dec 4;9:520. doi: 10.1186/1471-2105-9-520.

43.

Direct interaction between the inhibitor 2 and ceramide via sphingolipid-protein binding is involved in the regulation of protein phosphatase 2A activity and signaling.

Mukhopadhyay A, Saddoughi SA, Song P, Sultan I, Ponnusamy S, Senkal CE, Snook CF, Arnold HK, Sears RC, Hannun YA, Ogretmen B.

FASEB J. 2009 Mar;23(3):751-63. doi: 10.1096/fj.08-120550. Epub 2008 Nov 21.

44.

A tumor suppressor role for PP2A-B56alpha through negative regulation of c-Myc and other key oncoproteins.

Arnold HK, Sears RC.

Cancer Metastasis Rev. 2008 Jun;27(2):147-58. doi: 10.1007/s10555-008-9128-9. Review.

45.

Negative regulation of Pim-1 protein kinase levels by the B56beta subunit of PP2A.

Ma J, Arnold HK, Lilly MB, Sears RC, Kraft AS.

Oncogene. 2007 Aug 2;26(35):5145-53. Epub 2007 Feb 12.

PMID:
17297438
46.

A conserved pathway that controls c-Myc protein stability through opposing phosphorylation events occurs in yeast.

Escamilla-Powers JR, Sears RC.

J Biol Chem. 2007 Feb 23;282(8):5432-42. Epub 2006 Dec 27.

47.

Aberrant stabilization of c-Myc protein in some lymphoblastic leukemias.

Malempati S, Tibbitts D, Cunningham M, Akkari Y, Olson S, Fan G, Sears RC.

Leukemia. 2006 Sep;20(9):1572-81. Epub 2006 Jul 20.

49.

The life cycle of C-myc: from synthesis to degradation.

Sears RC.

Cell Cycle. 2004 Sep;3(9):1133-7. Epub 2004 Sep 5. Review.

PMID:
15467447
50.

Signaling networks that link cell proliferation and cell fate.

Sears RC, Nevins JR.

J Biol Chem. 2002 Apr 5;277(14):11617-20. Epub 2002 Jan 22. Review. No abstract available.

Supplemental Content

Loading ...
Support Center